Injection planes, and why they decide what you stock

A range creeps. It starts with two fillers and arrives, without anyone deciding, at nine. Some of that is brand loyalty and some is sampling, but a large part of it is structural: products are formulated for placement at particular depths, and a clinic treating across the face needs coverage across those depths.

Understanding the vocabulary is enough to make the stock sheet legible. You do not need to make the clinical decision to see why the shelf looks the way it does.

The three terms, plainly

These describe where in the tissue a product is placed, from shallowest to deepest. They are anatomical descriptions, not instructions.

• Subdermal — immediately beneath the skin itself, the most superficial of the three.
• Deep fat — within the fat compartments that sit below that layer.
• Supraperiosteal — deepest, against the periosteum, the membrane covering the bone.

Which of these applies to any given product, in any given region, is a clinical judgement made by the practitioner against the manufacturer's instructions for use. It is not something a wholesaler decides and it is not something this article will tell you.

Why manufacturers make more than one

Products intended for different placements are formulated differently. Manufacturers publish which placement theirs is intended for, and the characteristics they publish alongside it — how the gel behaves under pressure, how cohesive it is, what particle structure it has — are the ones relevant to that intended use.

The practical consequence for a buyer is simple. Two syringes from the same brand, at similar prices, in similar boxes, can be intended for entirely different placements. They are not two units of one line. They are two lines.

What the vocabulary is worth at reorder time

Two mistakes get made on stock sheets, and both come from treating placement as a detail rather than as the thing that separates one line from another.

The first is duplication. A clinic adds a product, does not register that it overlaps with something already held, and ends up with two lines competing for the same use — which halves the turnover of each and doubles the exposure to expiry. The second is a gap nobody notices until a Tuesday morning: the range covers three placements well and a fourth not at all, and the shortfall only surfaces when a treatment is already booked.

Both are visible the moment the stock sheet has a column for intended placement. Most do not.

Before a new line joins the shelf

• The intended placement, taken from the manufacturer's instructions for use rather than from a sales sheet or a catalogue summary
• Whether anything already on the shelf is intended for the same placement, and if so what this one is for that the other is not
• Pack size and pack contents, since a product used in smaller amounts per treatment turns over differently even at the same price
• What the reorder interval will realistically be, which follows from how often the treatments that use it are actually booked
• Whether the bulk tier you are tempted by assumes a turnover this line will genuinely reach

Substitution is not a stock decision

The one thing worth saying flatly: a product formulated for one placement is not a stand-in for a product formulated for another, and whether any substitution is appropriate is a clinical call. A stockout is a poor reason to raise it, and the morning of the appointment is a poor time.

Which is really an argument for the stock sheet. A range that is understood one line at a time will drift into overlaps and gaps; a range that is understood by what each line is for stays about the size it needs to be. The vocabulary is the cheap part — reading the intended placement off the IFU takes a minute per product, once.